INDOBORAX Indo Borax & Chemicals Q1 FY27 results (Apr–Jun 2026) and concall
Indo Borax & Chemicals Limited delivered a strong Q1 FY27 with significant revenue and profit growth, driven by operational efficiencies. The quarter was highlighted by the strategic acquisition of Kronox Lab Sciences, aimed at diversifying its specialty chemicals portfolio. While the company provided positive full-year guidance, it cautioned about potential Q2 softness due to seasonal factors and high raw material costs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 29.6%, net profit up 60.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 38 | 38 | 50 | 54 | 58 +53% | 41 +8% | 63 +26% | 70 +30% |
| EBITDA | 9 | 10 | 10 | 12 | 10 +11% | 9 −10% | 13 +30% | 20 +67% |
| Net profit | 9 | 9 | 10 | 10 | 16 +78% | 9 +0% | 15 +50% | 16 +60% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.





